Benjamin P. Saylor
Saylor is content managing editor for Urology Times.
Risks higher with salvage AUS, but success is possible
Although salvage artificial urinary sphincter implantations are associated with an increased risk of recurrent erosion/infection requiring explantation, excellent long-term success rates can be attained in carefully selected patients, according to a recent study.
Androgen receptor inhibitor shows significant PFS increase
Androgen receptor inhibitor shows significant PFS increase
Recent phase II results point to the efficacy of the prostate cancer agent enzalutamide (XTANDI) when compared with bicalutamide (Casodex).
European data on PCa assay comparable to U.S. findings
European data on PCa assay comparable to U.S. findings
Results presented at the EAU Annual Congress bolster the Prolaris test’s efficacy in determining disease aggressiveness.
Targeted biopsy, PSA ‘choice’ among best-read articles
Other highly read UT articles this month include a large comparison of robotic and open RP, answers to your questions about coding for prostate biopsy, and several studies about risks for low and high T.
Testosterone nasal gel shows safety, efficacy
A new testosterone nasal gel (Natesto) is safe and efficacious, according to phase III data presented at the Endocrine Society annual meeting in San Diego.
Studies examine risk factors for low, high T
A handful of new studies reveal new information about risk factors for both low and high testosterone as well as the potential risks associated with each.
FDA moves to change TRT product labeling
The FDA acted on recommendations from one of its advisory committees by requiring manufacturers of testosterone therapies to make label changes that restrict the drugs’ usage.
One-minute frailty test may improve surgical outcomes
One minute of a physician’s time could help determine how likely a urologic patient is to experience complications after an operation, say researchers from Emory University School of Medicine, Atlanta.
Coverage for OAB nerve stim device expands
Coverage for OAB nerve stim device expands
Uroplasty, Inc. announced that Cigna has written a positive coverage policy for percutaneous tibial nerve stimulation delivered via Uroplasty's Urgent PC neuromodulation system for treatment of overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence.
Top read in February: AUA statement on NPs/PAs
Catch up on February’s best-read Urology Times articles, including our coverage of the AUA’s recent statement on NPs/PAs, a malpractice case involving removal of a cancer-free testicle, and a Q&A on diversity in urology.